Purpose: The aim of this study was to assess the potential of machine learning with multiparametric magnetic resonance imaging (mpMRI) for the early prediction of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and of survival outcomes in breast cancer patients. Materials and Methods: This institutional review board-approved prospective study included 38 women (median age, 46.5 years; range, 25-70 years) with breast cancer who were scheduled for NAC and underwent mpMRI of the breast at 3 T with dynamic contrast-enhanced (DCE), diffusion-weighted imaging (DWI), and T2-weighted imaging before and after 2 cycles of NAC. For each lesion, 23 features were extracted: qualitative T2-weighted and DCE-MRI features according to BI-RADS (Breast Imaging Reporting and Data System), quantitative pharmacokinetic DCE features (mean plasma flow, volume distribution, mean transit time), and DWI apparent diffusion coefficient (ADC) values. To apply machine learning to mpMRI, 8 classifiers including linear support vector machine, linear discriminant analysis, logistic regression, random forests, stochastic gradient descent, decision tree, adaptive boosting, and extreme gradient boosting (XGBoost) were used to rank the features. Histopathologic residual cancer burden (RCB) class (with RCB 0 being a pCR), recurrence-free survival (RFS), and disease-specific survival (DSS) were used as the standards of reference. Classification accuracy with area under the receiving operating characteristic curve (AUC) was assessed using all the extracted qualitative and quantitative features for pCR as defined by RCB class, RFS, and DSS using recursive feature elimination. To overcome overfitting, 4-fold cross-validation was used. Results: Machine learning with mpMRI achieved stable performance as shown by mean classification accuracies for the prediction of RCB class (AUC, 0.86) and DSS (AUC, 0.92) based on XGBoost and the prediction of RFS (AUC, 0.83) with logistic regression. The XGBoost classifier achieved the most stable performance with high accuracies compared with other classifiers. The most relevant features for the prediction of RCB class were as follows: changes in lesion size, complete pattern of shrinkage, and mean transit time on DCE-MRI; minimum ADC on DWI; and peritumoral edema on T2-weighted imaging. The most relevant features for prediction of RFS were as follows: volume distribution, mean plasma flow, and mean transit time; DCE-MRI lesion size; minimum, maximum, and mean ADC with DWI. The most relevant features for prediction of DSS were as follows: lesion size, volume distribution, and mean plasma flow on DCE-MRI, and maximum ADC with DWI. Conclusions: Machine learning with mpMRI of the breast enables early prediction of pCR to NAC as well as survival outcomes in breast cancer patients with high accuracy and thus may provide valuable predictive information to guide treatment decisions.
N eoadjuvant chemotherapy (NAC) as a standard of care offers several advantages such as increased rates of breast-conserving surgery and decreased axillary dissection. 1 The recent St Gallen consensus statement also indicates that NAC is widely used in TNBC and HER2+ subtypes of breast cancer, with this preference being extended to women who are eligible for breast conservation at diagnosis. 1 This new development is driven by response-guided assessment of prognosis, adjuvant treatment, and follow-up. The achievement of a pathological complete response (pCR) is significantly associated with improved disease-free and overall survival 2 in breast cancer patients undergoing NAC, whereas poor outcome after NAC is associated with less favorable prognosis. 3 Nevertheless, a pCR is achieved in only 30% of the patients after the completion of NAC and thus determining factors and an accurate means to predict treatment response as early as possible are desirable for identifying patients who do not benefit from NAC. 2 Several studies have demonstrated that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is the most sensitive method for the assessment and prediction of treatment response to NAC. [4] [5] [6] [7] [8] In addition, it has been demonstrated that multiparametric MRI (mpMRI) using morphological as well as additional functional parameters such as diffusion-weighted imaging (DWI) has the potential for improving the prediction of treatment response. 6, [8] [9] [10] [11] [12] Further, with advances in the field of bioinformatics, new approaches to medical imaging data analysis for predictive modeling in cancer evaluation have been developed. 13 In contrast to traditional statistical approaches, which usually consider a limited finite set of hypotheses and evaluate them, machine learning approaches have the capability to generate models for prediction by extensively searching through the model and parameter space and thus have been embraced for predictive modeling and decision-making in biomedicine. [14] [15] [16] [17] [18] Inital results have demonstrated the potential for the application of machine learning with MRI almost exclusively on DCE-MRI for prediction of treatment response, but the potential of mpMRI in this context has not yet been fully explored. [19] [20] [21] Therefore, the aim of this study was to assess the feasibility of machine learning with mpMRI using T2-weighted MRI, DCE-MRI, and DWI for the early prediction of pCR to NAC, recurrence-free survival (RFS), and disease-specific survival (DSS) in breast cancer patients.
MATERIALS AND METHODS
The institutional review board approved this prospective, singleinstitution study and retrospective radiomics data analysis. All patients gave written informed consent.
Patients
Between April 2008 and April 2013, 38 patients (median age, 46.5 years; range, 25-70 years) who fulfilled the following inclusion criteria were enrolled in this study: ≥18 years, not pregnant, not breastfeeding, and new diagnosis of histopathologically proven breast cancer scheduled for NAC (BI-RADS [Breast Imaging Reporting and Data System] 6, biopsy-proven malignancy). Exclusion criteria were previous treatment and contraindications for MRI or MRI contrast agents. All patients underwent mpMRI 2 weeks before initiation and after 2 cycles of NAC. For all patients, the following information were recorded at therapy: age, type and start date of systemic therapy, histologic type, tumor grade, receptor status, tumor proliferation rate (ki67), nodal status, date of progression (local recurrence, distant metastases) to determine duration (months) of RFS, and date and cause of death or date of last follow-up to determine duration (months) of DSS.
Magnetic Resonance Imaging
All patients underwent mpMRI of the breast at 3 T in the prone position (Trio Tim; Siemens Medical Solutions, Erlangen, Germany) with a dedicated 4-channel breast coil (In Vivo, Orlando, FL). The following protocol was used before and during NAC: ; 144 slices; spatial resolution, 0.9 Â 0.9 Â 1 mm; temporal interpolation factor 2; temporal resolution, 14 seconds; matrix, 384 Â 384; one average; center k-space region with a resampling A standard dose (0.1 mmol/kg body weight) of gadoterate meglumine (Gd-DOTA; Dotarem; Guerbet, France) was injected intravenously as a bolus at 4 mL/s followed by a saline flush. The total MRI examination time was approximately 10 to 12 minutes.
Image Analysis
Multiparametric magnetic resonance imaging data were evaluated by 2 experienced breast radiologists (K.P., 12 years of experience; G.W., 5 years of experience). Qualitative and quantitative imaging features were extracted from baseline and follow-up mpMRI images. These features were used as attributes to feed machine learning classifiers.
Qualitative Imaging Features
For all lesions size (largest diameter) in the right-left (RL), craniocaudal, and anterior-posterior (AP) direction, patterns of shrinkage (concentric, fragmentation, or complete) were recorded. Signal intensity on T2-weighted sequences (hypointense, isointense, or hyperintense) and the presence or absence of a peritumoral edema were noted. In DCE-MRI, tumors were classified as mass or non-mass-enhancing lesions. According to the fifth edition of the American College of Radiology and Breast Imaging Reporting and Data System, 23 the following descriptors were assessed for masses: shape (round, oval, and irregular), margins (circumscribed, irregular, and spiculated), and internal enhancement characteristics (homogeneous, heterogeneous, rim enhancement, and dark internal septations). For non-mass-enhancing lesions, the distribution (focal, linear, regional, segmental, multiple, and diffuse), internal enhancement pattern (homogeneous, heterogeneous, clumped, and clustered ring), and symmetry (symmetric and asymmetric) were evaluated.
Quantitative Imaging Features
For pharmacokinetic assessment of DCE-MRI, the mean plasma flow, volume distribution, and mean transit time were assessed with parametric maps using a 3-dimensional-based region of interest (ROI) segmentation approach using the UMM-perfusion tool of OSIRIX ® version 7.0 (University of Heidelberg). 24 Diffusion-weighted imaging high b-value (ie, 850 s/mm 2 ) images were qualitatively assessed for hyperintense regions corresponding to the lesion on DCE-MRI. The slice with the greatest representative portion of the tumor was selected. One 2-dimensional ROI with a minimum area of 1 mm 2 was drawn on the part of the tumor with the lowest apparent diffusion coefficient (ADC) using OSIRIX, and the mean, minimum, and maximum ADC was recorded.
Histopathologic Diagnosis
All surgical specimens were analyzed by 2 breast pathologists (Z.B., 7 years of experience in breast pathology; S.A., 7 years of experience in breast pathology). The residual cancer burden (RCB) score was used for assessment of pathological treatment response. The RCB score is as continuous variable that is calculated using the following parameters: (1) primary tumor bed area (mm 2 ), overall cancer cellularity (% of area), and percentage of cancer that is in situ disease (%); and (2) the number of positive lymph nodes and diameter of largest metastasis (millimeter). 25 Scores were then expressed as 4 RCB classes: RCB 0 is consistent with pCR with no evidence of residual disease. If residual disease is present, this was classified into 3 categories: RCB 1, minimal residual disease present; RCB 2, moderate response to neoadjuvant disease and moderate residual disease burden; and RCB 3, extensive residual disease burden. 26 
Survival Outcomes
For the assessment of RFS and DSS, all patients underwent clinical and imaging follow-up with mammography, sonography, or computed tomography until progression, followed by routine follow-up until death. At the discretion of the treating physician, some patients were also followed with MRI of the breast and positron emission tomography/ computed tomography scans. All local and distant recurrences were histopathologically verified. 27 
Machine Learning
Eight robust machine learning algorithms including linear support vector machine (SVM), linear discriminant analysis (LDA), Anthracycline/taxane-containing 2 8
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Anthracycline logistic regression (LR), random forests (RF), stochastic gradient descent (SGD), decision tree, adaptive boosting (AdaBoost), and extreme gradient boosting (XGBoost) were applied to the mpMRI data to predict RCB class, RFS, and DSS. For details on the individual classifiers, refer to Supplementary S1, Supplemental Digital Content, http://links.lww.com/RLI/A406. For the purposes of predicting RCB class, machine learning class 1 denoted a complete (RCB 0) and machine learning class 0 an incomplete pathologic response (RCB class 1, 2, 3). Each specific learning algorithm was designed to provide the best model to fit the input data and predict the class labels correctly. Optimum ranking of the features based on their importance in the models was reported using recursive feature elimination. To overcome overfitting, 4-fold cross-validation was used to differentiate between 2 groups of each defined classes. Area under the receiver operation characteristic curve (AUC) was used as the classification metric. 
RESULTS
Of the 38 patients in the study, after completion of NAC, 9 patients were classified as RCB class 0, 7 as RCB class 1, 14 as RCB class 2, and 8 as RCB class 3. Tumor histopathology, grade, and receptor status proliferation rate stratified by RCB class are summarized in Table 1 . Neoadjuvant chemotherapy regimens and RCB class for all patients are listed in Table 2 . The median follow-up time for all patients was 65 months (range, 6-119 months). Eight patients (21.05%) progressed during the follow-up period after a median interval of 16 months (range, 1-56 months), and 4 patients (10.52%) died of breast cancer during the follow-up period at a median interval of 53 months (range, 12-87 months).
Based on recursive feature elimination, feature importance in the mpMRI model for prediction of RCB class, RFS, and DSS are summarized in Figure 1 . For prediction of RCB class, RFS, and DSS, qualitative and quantitative features from all mpMRI sequences, that is, T2-weighted, DCE, and DWI, were necessary. The most relevant features for prediction of RCB class were qualitative features including changes in lesion size (RL, craniocaudal, and AP) and complete pattern of shrinkage on DCE-MRI, quantitative pharmacokinetic features including mean transit time with DCE-MRI, peritumoral edema on T2-weighted imaging, and minimum ADC with DWI. For prediction of RFS, the most relevant features were the qualitative feature of lesion size on DCE-MRI (RL, AP), the quantitative features of volume distribution, and mean plasma flow and ADC with DWI. For prediction of DSS, the qualitative feature of lesion size (RL, AP), the quantitative pharmacokinetic features of volume distribution, and mean plasma flow and maximum ADC with DWI were most relevant. Figure 2 presents the boxplot illustration of the performance of recursive feature elimination along with 8 machine learning classifiers in prediction of RCB class ( Fig. 2A) , RFS (Fig. 2B) , and DSS (Fig. 2C) . Table 3 summarizes the AUCs for all classifier models. To identify the most stable classifier with high accuracy and low variance for predicting RCB class, RFS, and DSS, radar plot presentations of the mean AUC and the best AUC of the 8 machine learning classifiers were calculated (Fig. 3) . XGBoost outperformed all other classifier models including SVM, LDA, LR, RF, SGD, decision tree, and AdaBoost in the prediction of RCB class and DSS, with AUCs ranging from 0.8577 to 0.9430 and 0.9052 to 0.92 for RCB class and DSS, respectively. For the prediction of RFS, LR showed better performance with AUCs ranging from 0.8259 to 0.8666 (~3% better than XGBoost) (Fig. 4) ; however, it should be noted that XGBoost showed a more stable performance (less variance) in prediction of all 3 classes (Table 3) .
DISCUSSION
In this study, we applied machine learning to mpMRI of the breast for early prediction of pCR to NAC and survival outcomes in breast cancer patients. Machine learning with mpMRI allowed prediction of pCR (best/mean AUC, 0.94/0.86) and survival outcomes (RFS best/mean AUC, 0.83/0.77; DSS best/mean AUC, 0.92/0.91) with high accuracy. Qualitative and quantitative features from all MRI sequences were necessary for prediction of RCB class, RFS, and DSS, thus supporting the use of an mpMRI approach. Of all machine learning classifier models, the XGBoost classifier model outperformed all other models in the prediction of pCR and DSS. Only for RFS, the LR classifier model showed a slightly better accuracy (~3%) yet the XGBoost model is more stable.
In breast cancer patients undergoing NAC, the achievement of a pCR is significantly associated with improved disease-free and overall survival, 2 and yet is achieved in only 30% of patients. 2 Therefore, means for early prediction of treatment response to identify women, who are less likely to achieve pCR to standard NAC and are therefore candidates for alternative treatment approaches, may be pivotal. The application of machine learning to mpMRI to improve its predictive capabilities is an important step toward precision medicine in breast cancer.
In contrast to initial prior studies, we used a wealth of qualitative and quantitative parameters extracted from mpMRI including T2-weighted MRI, DCE-MRI, and ADC (minimum, maximum, mean) with DWI. We extracted 23 features per lesion and used 8 robust machine learning algorithms including SVM, LDA, LR, RF, SGD, decision tree, AdaBoost, and XGBoost. We showed that both qualititve and quantitive features from mpMRI are important for accurate prediction of pCR. Such features include changes in lesion size and complete pattern of shrinkage on DCE-MRI, mean transit time on DCE-MRI, minimum ADC with DWI, and peritumoral edema on T2-weighted imaging. We demonstrated that all classifiers predicted pCR, with XGBoost outperforming the others with a mean AUC of 0.8577 and best AUC of 0.9430. Several studies that have investigated DCE-MRI in this context have shown that functional imaging with or without texture analysis outperforms conventional imaging, paving the way for new, effective, and preferably noninvasive or minimally invasive approaches to predict treatment response. 8, [28] [29] [30] Previous studies that have explored utility of machine learning for improved prediction of pCR to NAC in breast cancer patients have so far almost exclusively focused on singleparametric DCE-MRI-derived kinetic features. [31] [32] [33] O'Flynn et al 12 have shown that machine learning algorithms such as LDA along with statistical methods based on DCE-MRI features such as enhancement Receiver operation characteristic (ROC) curves of mpMRI model using XGBoost classifier using 4-fold cross-validations in prediction of (A) RCB class and (B) RFS, and 3-fold cross-validation in prediction of (C) DSS. The solid orange lines present the mean ROC curve, the lighter lines illustrate the ROC curve for each fold, and the gray-shaded areas provide the confidence interval for the predictions using mpMRI model. fraction, tumor volume, initial area under the gadolinium curve, and pharmacokinetic parameters such as K trans and K ep can be used to predict patients in terms of responders and nonresponders to NAC. However, it should be noted that they have used only 7 features along with one machine learning algorithm based on 32 patients.
Mani et al 20 investigated the early prediction of the response to NAC, adding functional information from DWI to DCE-MRI as well as ultrasonographic, clinical, and histopathological information. Thirteen imaging features from quantitative DCE-MRI features; ADC mean with DWI; size on ultrasound; and 11 clinical parameters including age, clinically estimated tumor size, receptor status, proliferation rate, and node parameters were used for the predictive models. Three linear classifiers (Gaussian Naïve Bayes, LR, and Bayesian LR), 2 decision tree-based classifiers (CART36 and RF), 1 kernel-based classifier (SVM), and 1 rule learner (Ripper) in conjuntion with 3 feature selection methods (HITON-MB, Gram-Schmidt orthogonalization with a maximum number of 10 features output, and BLCD-MB) were used. In studies combining imaging and clinical data, Bayesian LR had the best performance with an AUC of 0.96. 20 In a follow-up study, the authors achieved similar results (AUC, 0.86) when expanding the number of variables derived from semiquantitve and quantitive DCE-MRI. 19 It has to be noted that, in this, the information of both invasive histopathologic assessement, clinical examination, and ultrasound was necessary. In our study, we solely relied on the qualitative and quantitive features extracted from 1 imaging modality, that is, mpMRI, achieving similar results with high accuarcies (best/mean AUC, 0.94/0.86).
In addition, we investigated the potential of applying machine learning with mpMRI for the prediction of RFS and DSS. We found that qualitative features such as lesion size together with quantitative pharmacokinetic features (volume distribution, mean plasma flow, and mean transit time) and ADC with DWI proved to be necessary for prediction of RFS and DSS. The XGBoost classifier model for mpMRI outperformed all other classifier models for DSS (mean AUC, 0.92) and was only minimally superseded for RFS by LR (mean AUC, 0.83) and showed the most stable performance of all models. So far, machine learning for prediction of survival outcomes in breast cancer has mainly used histopathologic and genomic data derived from invasive tissue sampling. 21, [34] [35] [36] [37] The results of the current study further provide evidence that functional MRI features can improve our understanding and prediction of cancer progression. 16, 21, 30, 38 Our data further highlight the potential of machine learning in this context and indicate that machine learning with noninvasive mpMRI might in the future be used as a cost-effective alternative to genomic assays such as OncotypeDx, MammaPrint, Mammostrat, and PAM50/Prosigna, which provide scores for risk of recurrence and guide treatment decisions. 39 A limitation of the current study is the small number of patients. At the start of the study, patients routinely underwent pretreatment staging with MRI and MRI before surgery for assessment of residual disease. Participation in this study required an additional MRI examination, which limited compliance. As mpMRI has now been established in this context, validation of the current results pending adequate patient follow-up is the focus of an ongoing study. We used qualitative and quantitative features that can be routinely extracted from mpMRI, which required human input for lesion identification and evaluation. Such interobserver or intraobserver variability may affect the extracted imaging features, and in turn, may affect the prediction of pCR, PFS, and DSS. This potential effect should be a topic of future studies.
In conclusion, machine learning with mpMRI of the breast enables early prediction of pCR to NAC and of survival outcomes in breast cancer patients with high accuracy. The integration of machine learning with mpMRI may provide valuable predictive information on treatment outcomes and risk of recurrence to guide treatment decisions and thus is a pivotal step for the realization of precision medicine in breast cancer.
